Amneal Sets $200m Sales Ambition For Biosimilar Trio
Looking To Expand Portfolio With Licensing Deals For Early-Entry Opportunities
Amneal management has offered additional detail on the firm’s burgeoning biosimilars business, revealing a “peak” sales estimate of $200m for its current roster of three products as well as indicating plans to expand its pipeline both through licensing and internal development.
You may also be interested in...
As Amneal reported first-quarter results, the firm’s management pointed to a number of specific product opportunities on the horizon as the company seeks to maintain growth momentum.
Ahead of revealing its full first-quarter results, Amneal has released limited preliminary details of its financials for the first three months of 2023, pointing to double-digit sales and profit growth in Q1.
With Amneal delivering what it described as a “solid” set of financials for 2022, the company has reaffirmed that it sees more value in moving increasingly into complex generics and bolstering its nascent biosimilars business.